Ado-Trastuzumab Emtansine and breast feeding
No information is available on the clinical use of ado-trastuzumab during breastfeeding. Because trastuzumab is a large protein molecule with a molecular weight of 145,531, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. However, ado-trastuzumab emtansine also contains the small molecule cytotoxin, DM1, the manufacturer recommends avoiding breastfeeding during and for 7 months following ado-trastuzumab emtansine therapy.
Up to date info
Alternative drugs - Ado-Trastuzumab Emtansine and breast feeding
Suggested alternatives on Ado-Trastuzumab Emtansine and breast feeding, when available and appropriate.
Breast feeding and drugs